(Q44334198)

2 December 2017

title

The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone (English)

1 reference

2 December 2017

0 references

1 reference

1 reference

D T Beattie

1

1 reference

2 December 2017

M Cheruvu

2

1 reference

2 December 2017

N Mai

3

1 reference

2 December 2017

M O'Keefe

4

1 reference

2 December 2017

S Johnson-Rabidoux

5

1 reference

2 December 2017

C Peterson

6

1 reference

2 December 2017

E Kaufman

7

1 reference

2 December 2017

R Vickery

8

1 reference

2 December 2017

language of work or name

1 reference

6 March 2007

1 reference

Naunyn-Schmiedeberg's Archives of Pharmacology

2 December 2017

published in

1 reference

2 December 2017

volume

375

1 reference

2 December 2017

issue

3

1 reference

2 December 2017

page(s)

205-220

1 reference

Alterations in the expression of G-proteins and regulation of adenylate cyclase in human neuroblastoma SH-SY5Y cells chronically exposed to low-efficacy mu-opioids.

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00210-007-0146-X

Model of opiate dependence in the guinea-pig isolated ileum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-007-0146-X

Pharmacological characterization of opiate physical dependence in the isolated ileum of the guinea-pig

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-007-0146-X

Acute withdrawal after bremazocine and the interaction between mu- and kappa-opioid receptors in isolated gut tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-007-0146-X

Side effects of morphine administration in cancer patients

21 January 2018

1 reference

12 December 2020

Incidence, prevalence, and management of opioid bowel dysfunction

1 reference

12 December 2020

Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial

1 reference

12 December 2020

Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects.

1 reference

12 December 2020

Naloxone-induced depolarization and synaptic activation of myenteric neurons in morphine-dependent guinea pig ileum.

1 reference

12 December 2020

Studies in vitro with ICI 174,864, [D-Pen2, D-Pen5]-enkephalin (DPDPE) and [D-Ala2, NMePhe4, Gly-ol]-enkephalin (DAGO).

1 reference

12 December 2020

[3H]U-69593 a highly selective ligand for the opioid kappa receptor

1 reference

12 December 2020

Some quantitative uses of drug antagonists

1 reference

12 December 2020

Opioid-induced bowel dysfunction: pathophysiology and potential new therapies

1 reference

12 December 2020

Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study

1 reference

12 December 2020

Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders

1 reference

12 December 2020

5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist

1 reference

12 December 2020

Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy

1 reference

12 December 2020

Synthesis of trans-3,4-Dimethyl-4-(3-hydroxyphenyl)piperidine Opioid Antagonists: Application of the Cis-Thermal Elimination of Carbonates to Alkaloid Synthesis

1 reference

12 December 2020

Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial.

1 reference

12 December 2020

Endomorphin-1 and endomorphin-2 activate mu-opioid receptors in myenteric neurons of the guinea-pig small intestine

1 reference

12 December 2020

Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist

1 reference

12 December 2020

Mu-opioid receptor desensitization in mature rat neurons: lack of interaction between DAMGO and morphine.

1 reference

12 December 2020

Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine

1 reference

12 December 2020

The use of quaternary narcotic antagonists in opiate research

1 reference

12 December 2020

Chronic morphine augments G(beta)(gamma)/Gs(alpha) stimulation of adenylyl cyclase: relevance to opioid tolerance

1 reference

12 December 2020

Insights into opioid action in the intestinal tract

1 reference

12 December 2020

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

1 reference

12 December 2020

Involvement of mu- and kappa-, but not delta-, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine.

1 reference

12 December 2020

Prevention of opioid side effects

1 reference

12 December 2020

A potent and selective endogenous agonist for the mu-opiate receptor

1 reference

12 December 2020

[(3)H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists

1 reference

12 December 2020

Pharmacological examination of contractile responses of the guinea-pig isolated ileum produced by mu-opioid receptor antagonists in the presence of, and following exposure to, morphine

1 reference

12 December 2020

Molecular biology and pharmacology of cloned opioid receptors

1 reference

12 December 2020

Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus

1 reference

12 December 2020

Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors.

1 reference

12 December 2020

Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence

1 reference

12 December 2020

Treatment of opioid-induced constipation with oral naloxone: A pilot study

1 reference

12 December 2020

A review of the potential role of methylnaltrexone in opioid bowel dysfunction

1 reference

12 December 2020

The kappa-opioid receptor agonist U50,488H induces acute physical dependence in guinea-pigs

1 reference

12 December 2020

Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo

1 reference

12 December 2020

Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities.

1 reference

12 December 2020

Pharmacological management of cancer pain.

1 reference

12 December 2020

Alvimopan, a selective peripherally acting mu-opioid antagonist

1 reference

12 December 2020

Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans

1 reference

12 December 2020

Oral naloxone reverses opioid-associated constipation

1 reference

12 December 2020

Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist

1 reference

12 December 2020

Inhibitory effect of endomorphin-1 and -2 on acetylcholine release from myenteric plexus of guinea pig ileum

1 reference

12 December 2020

Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library

1 reference

12 December 2020

Na+ modulation, inverse agonism, and anorectic potency of 4-phenylpiperidine opioid antagonists

1 reference

12 December 2020

Na+-dependent high affinity binding of [3H]LY515300, a 3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid receptor inverse agonist

1 reference

12 December 2020

Preclinical studies of opioids and opioid antagonists on gastrointestinal function

1 reference

12 December 2020

10.1007/S00210-007-0146-X

Identifiers

DOI

1 reference

2 December 2017

1 reference